从中华交易服务香港生物科技指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中华交易服务香港生物科技指数持仓样本的行业来看，生物药品占比56.98%、制药与生物科技服务 占比24.70%、化学药占比16.03%、医疗器械占比2.29%。 金融界6月24日消息，上证指数低开高走，中华交易服务香港生物科技指数 (中华香港生物科技， CESHKB)上涨3.66%，报7559.76点，成交额121.13亿元。 数据统计显示，中华交易服务香港生物科技指数近一个月上涨15.96%，近三个月上涨28.51%，年至今 上涨62.76%。 据了解，"中华交易服务香港生物科技指数由中华证券交易服务有限公司(中华交易服务)委托中证指数 有限公司(中证指数)进行编制，指数编制方案由中华交易服务以及中证指数共同确定。中华交易服务香 港生物科技指数(中华香港生物科技)为证券价格指数，旨在反映于香港上市的生物科技公司的整体表 现"该指数以2014年12月12日为基日，以2000.0点为基点。 从指数持仓来看，中华交易服务香港生物科技指数十大权重分别为：康方生物（10.79%）、信达生物 （10.03%）、百济神州（9.56%） ...

Group 1: Market Overview - The market has seen adjustments in hot sectors, with cyclical commodities like coking coal, aluminum, and Brent crude oil performing well due to the Middle East crisis affecting global commodity supply [2] - The North China 50 index has adjusted, influenced by discussions around micro-cap stock trading congestion, with cautious investors taking action [2] - A weekly review of A-shares shows bank stocks leading in gains, while sectors like beauty care, pharmaceuticals, textiles, and social services have seen declines [2] Group 2: Middle East Risk - The Middle East crisis is currently limited to Iran, but concerns are growing about the potential for escalation following U.S. airstrikes on Iranian nuclear facilities [3] - Predictions suggest that if Iran expands its attacks and blocks the Strait of Hormuz, oil prices could surge to $120-130 per barrel, leading to high global inflation and reduced manufacturing profits [3] - Analysis indicates that U.S. actions may be politically motivated to alleviate internal pressures, with a focus on avoiding ground troop deployment [3] Group 3: China Asset Revaluation - The recent Lujiazui Forum indicated a policy tone favoring openness, which could release policy dividends for the revaluation of Chinese assets [5] - Foreign Direct Investment (FDI) in China has shown a decline, with actual foreign investment amounting to 358.19 billion yuan in the first five months of 2025, down 13.2% year-on-year [5][6] - The structure of FDI shows positive trends in high-tech industries, with significant growth in sectors like e-commerce services and aerospace manufacturing [6] Group 4: Tax Revenue Insights - National public budget revenue for January to May 2025 was 96,623 billion yuan, a slight decrease of 0.3% year-on-year, with land use rights revenue down 11.9% [7] - The probability of a real estate market resurgence is low, as indicated by declining property-related tax revenues [7] - Securities transaction stamp duty increased by 52.4% year-on-year, reflecting heightened market activity and the importance of the stock market in asset revaluation [8] Group 5: Non-Tax Revenue and Market Dynamics - Non-tax revenue grew by 6.2% year-on-year, indicating a shift in focus from external factors to internal reforms and adjustments in interests [9] - The government is increasingly normalizing its behavior in revenue collection, which is crucial for market vitality and asset revaluation [9] Group 6: Long-Term Asset Revaluation - While external risk premiums suggest a foundation for asset revaluation in China, internal conditions still require improvement for a complete revaluation [10] - The restructuring of international order and adjustments in China's leading industries present ongoing investment opportunities [11]

Group 1 - The number of newly established foreign-invested enterprises in China increased by 10.4% year-on-year, reaching 24,018 from January to May 2025, indicating strong confidence from foreign investors in long-term investments in China [1] - The actual foreign investment amount decreased by 13.2% year-on-year to 358.19 billion RMB during the same period, highlighting a divergence between the number of new enterprises and the actual investment amount [1] - The manufacturing sector attracted 91.52 billion RMB in actual foreign investment, while the service sector received 259.64 billion RMB, with high-tech industries drawing 109.04 billion RMB [1] Group 2 - The service industry has become the primary area for foreign investment inflows, with the Chinese government expanding pilot programs to promote service sector openness in nine additional cities [2] - Investment from ASEAN countries grew by 20.5%, while Japan and the UK saw increases of 70.2% and 60.9%, respectively, reflecting the positive impact of regional economic integration [2] - The implementation of RCEP has contributed to stable growth in foreign investment from ASEAN and Japan, emphasizing the benefits of regional economic cooperation [2] Group 3 - Future efforts should focus on optimizing the business environment, expanding open sectors, and enhancing service guarantees for foreign investors [3] - Reducing the negative list for foreign investment access will allow foreign enterprises to fully benefit from China's growing market [3] - Strengthening government services and legal protections will provide a more stable and predictable development environment for foreign investments [3]

Core Insights - The Ministry of Commerce announced that from January to May 2025, a total of 24,018 new foreign-invested enterprises were established in China, representing a year-on-year increase of 10.4% [1] - However, the actual utilized foreign capital amounted to 358.19 billion RMB, showing a year-on-year decrease of 13.2% [1] Industry Analysis - In terms of industry, the actual utilized foreign capital in the manufacturing sector was 91.52 billion RMB, while the service sector saw 259.64 billion RMB [1] - High-tech industries attracted 109.04 billion RMB in actual foreign investment, with significant growth in specific sectors: e-commerce services increased by 146%, aerospace equipment manufacturing by 74.9%, chemical pharmaceuticals by 59.2%, and medical instruments and devices by 20% [1] Source Region Insights - From the perspective of source regions, foreign investment from ASEAN countries grew by 20.5% [1] - Investments from Japan, the UK, South Korea, and Germany increased by 70.2%, 60.9%, 10.3%, and 7.1% respectively [1]

Group 1 - The core viewpoint of the news is that the China Securities Medicine and Health Dividend Index has shown positive performance, with a 6.35% increase over the past month and a 5.98% increase over the past three months, while year-to-date it has risen by 1.32% [2] - The index is designed to reflect the overall performance of high dividend yield securities in various industries, using a dividend yield weighted calculation method [2] - The index's top ten holdings include Mingde Biological (4.22%), Huate Dain (3.3%), Lingrui Pharmaceutical (3.21%), and others, indicating a diverse portfolio within the healthcare sector [2] Group 2 - The index is composed of stocks with a cash dividend yield greater than 0.5% and ranks within the top 80% of average daily trading volume over the past year, with annual adjustments made to the sample [3] - The index's holdings are primarily in traditional Chinese medicine (36.05%), chemical drugs (22.28%), and medical services (17.54%), showcasing a focus on various segments of the healthcare industry [2] - The index is maintained with specific rules regarding sample adjustments, including a limit on the proportion of changes and conditions for excluding stocks that do not meet the criteria [3]

商务部数据显示，2025年1-4月，全国新设立外商投资企业18832家，同比增长12.1%；实际使用外资金 额3207.8亿元人民币，同比下降10.9%。从行业看，制造业实际使用外资840.6亿元人民币，服务业实际 使用外资2312.5亿元人民币。高技术产业实际使用外资967.1亿元人民币，其中，电子商务服务业、航空 航天器及设备制造业、化学药品制造业、医疗仪器设备及器械制造业实际使用外资分别增长137%、 86.2%、57.8%和4.9%。从来源地看，东盟地区实际对华投资增长42.9%，日本、瑞士、英国、韩国、德 国实际对华投资分别增长74.2%、68.4%、54.6%、22.3%和12.3%（含通过自由港投资数据）。 ...

Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a recent increase of 9.41% over the past month, while it has decreased by 0.61% over the last three months and increased by 18.99% year-to-date [1] - The index consists of 50 listed companies involved in medical devices, medical business and services, pharmaceuticals, and biotechnology services, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The top ten weighted companies in the index include WuXi Biologics (16.6%), JD Health (11.41%), Alibaba Health (7.52%), Sinopharm (5.68%), WuXi AppTec (5.51%), Weigao Group (3.66%), Genscript Biotech (3.55%), Innovent Biologics (2.4%), CanSino Biologics (2.23%), and MicroPort Scientific (2.2%) [1] Group 2 - The industry composition of the index shows that medical business and services account for 35.62%, pharmaceutical and biotechnology services for 31.58%, medical devices for 11.75%, chemical drugs for 10.53%, biological drugs for 10.09%, and traditional Chinese medicine for 0.42% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or spin-offs [2]

长江商报奔腾新闻记者 徐佳 对外财务资助未按规定进行信披，哈三联（002900）（002900.SZ）及高管被罚。 5月5日晚间，哈三联披露公告称，公司及相关人员收到黑龙江证监局警示函。 警示函显示，经查，2022年7月至2023年7月，哈三联以支付预付款的形式向哈尔滨泰盛昌包装印刷有限 公司（以下简称"泰盛昌"）累计支付2250万元，泰盛昌未实际交货并退回相关款项；2023年1月至2024 年3月，哈三联以支付预付款的形式向中孚药业股份有限公司（以下简称"中孚药业"）累计支付2200万 元，中孚药业未实际交货，退回相关款项并支付利息。 黑龙江证监局认为，前述事项构成哈三联对外财务资助，公司未按规定履行相应的审议程序和信息披露 义务，违反了相关规定。公司董事长兼总经理、时任董事会秘书秦剑飞，财务总监赵志成，董事会秘书 梁延飞未按照规定履行勤勉尽责义务，对公司上述违规行为负有主要责任。 按照相关规定，黑龙江证监局决定对哈三联、秦剑飞、赵志成、梁延飞分别采取出具警示函的行政监管 措施，并记入证券期货市场诚信档案，公司及有关责任人需提交书面报告。 资料显示，哈三联主要从事化学药品制剂的研发、生产和销售，当前形成"医 ...

Core Viewpoint - Tonghe Pharmaceutical reported a revenue of 759 million yuan for 2024, a year-on-year increase of 5.1%, and a net profit attributable to shareholders of 107 million yuan, up 0.6% [1] Group 1: Company Performance - The company's operating cash flow net amount reached 285 million yuan, growing by 74.2% [1] - The company focuses on the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates, with a leading production capacity and product quality in China [2][3] - The company has over 600 various types of enamel and metal reaction kettles, with a total volume exceeding 3 million liters [2] Group 2: Market Outlook - The global active pharmaceutical ingredient (API) market is expected to see significant growth, with approximately 300 billion USD worth of original drugs set to lose patent protection from 2019 to 2026, leading to a potential API market increase of nearly 200 billion yuan [2] - China is a major global producer and supplier of APIs, and the implementation of centralized procurement policies is expected to enhance the concentration of pharmaceutical companies and increase the space for import substitution [3] Group 3: Strategic Focus - The company emphasizes focusing on its core business, avoiding diversification, and aims to strengthen its position in the chemical pharmaceutical industry [4] - The average R&D investment over the past three years accounted for 8.34% of sales, with increased focus on various therapeutic areas [4] - The company plans to enhance domestic market development while maintaining a strong export focus, aiming for simultaneous sales in both domestic and international markets [5]

Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a decline of 11.89% over the past month, an increase of 13.46% over the past three months, and a year-to-date increase of 8.75% [1] - The index consists of 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The index is based on a starting point of 1000.0 points as of December 31, 2018 [1] Group 2 - The top ten weighted companies in the index include WuXi Biologics (15.72%), JD Health (11.24%), Alibaba Health (7.31%), Sinopharm (5.92%), WuXi AppTec (5.0%), Kingstar BioTech (3.88%), Weigao Group (3.72%), CanSino Biologics (2.43%), MicroPort Medical (2.4%), and Innovent Biologics (2.35%) [1] - The index is exclusively composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - The industry composition of the index includes 35.98% in medical services, 30.61% in pharmaceuticals and biotechnology, 12.17% in medical devices, 10.73% in chemical drugs, 10.09% in biological drugs, and 0.42% in traditional Chinese medicine [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers and acquisitions [2]